GLP 1-S – 30 MG

GLP-1 S

GLP-1 S is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist approved for chronic weight management and glycemic control in adults with obesity or type 2 diabetes. It mimics endogenous GLP-1, acting on central and peripheral pathways to suppress appetite, delay gastric emptying, increase glucose-dependent insulin secretion, decrease glucagon release, and promote pancreatic β-cell growth.^[1][2]

Efficacy for Weight Loss & Obesity Management

Indicated for adults with BMI ≥30 kg/m² or ≥25 kg/m² with a weight-related comorbidity.^[3][2][4] In STEP 1 and STEP 3, mean weight loss at 68 weeks was 14.9% and 16.0%, respectively, vs 2.4% and 5.7% with placebo. Most participants achieved ≥10% loss, and over half achieved ≥15% loss.^[1][5–7] Benefits are maintained with continued therapy; discontinuation often leads to weight regain, underscoring the need for long-term treatment.^[1][5][7]

Glycemic Control & Cardiometabolic Benefits

• Significant reductions in HbA1c and fasting glucose in type 2 diabetes.^{[8–11][2][5]}
• Lowers blood pressure, improves lipid profiles, and reduces inflammatory markers (e.g., CRP).^[4][6]
• Recommended by ADA and AGA as a first-line pharmacologic option for weight management in adults with obesity and/or type 2 diabetes.^[11][2]

Cardiovascular & Renal Outcomes

• Reduces MACE, cardiovascular mortality, and all-cause mortality in high-risk populations per large trials/meta-analyses.^[12–15][4]
• Kidney-protective effects; recommended for CKD with type 2 diabetes.^[12][15][2]

Safety & Tolerability

• Most common AEs are GI (nausea, vomiting, diarrhea); discontinuation rates similar to placebo in trials.^[5–7]
• Rapid weight loss may increase risk of gallstones/hepatobiliary disorders.^[6]
• No consistent link with increased cancer or psychiatric AEs confirmed.^[7]
• Low hypoglycemia risk as monotherapy.^[8–10][2]

Clinical Considerations

• Use alongside nutrition and physical-activity interventions.^[1][2][6]
• Plan for long-term therapy; counsel on potential weight regain after stopping.^[1][5][7]
• Individualize therapy based on comorbidities, preferences, and access.^[2][7]

References

1. Elmaleh-Sachs A, Schwartz JL, Bramante CT, et al. JAMA. 2023;330(20):2000-2015.
2. Grunvald E, Shah R, Hernaez R, et al. AGA Guideline. Gastroenterology. 2022;163(5):1198-1225.
3. FDA Orange Book.
4. Joseph JJ, Deedwania P, Acharya T, et al. AHA Statement. Circulation. 2022;145(9):e722-e759.
5. Bergmann NC, Davies MJ, Lingvay I, Knop FK. Diabetes Obes Metab. 2023;25(1):18-35.
6. Wadden TA, Bailey TS, Billings LK, et al. STEP 3. JAMA. 2021;325(14):1403-1413.
7. Ferrara F, Bazzani D, Crivelli B, et al. Naunyn-Schmiedeberg’s Arch Pharmacol. 2025.
8. Blonde L, Fonseca V. Endocr Pract. 2018.
9. Sheahan KH, Wahlberg EA, Gilbert MP. Postgrad Med J. 2020;96:156-161.
10. Sharma D, Verma S, Vaidya S, et al. Biomed Pharmacother. 2018;108:952-962.
11. ADA/EASD Consensus. Diabetes Care. 2022;45(11):2753-2786.
12. Salama L, Sinn L. Am J Health-Syst Pharm. 2025.
13. Sachinidis A, Nikolic D, Stoian AP, et al. Metabolism. 2020;111:154343.
14. Drucker DJ. Diabetes. 2018;67(9):1710-1719.
15. Galli M, Benenati S, Laudani C, et al. J Am Coll Cardiol. 2025.
16. Knop FK, Aroda VR, do Vale RD, et al. OASIS-1. Lancet. 2023;402:705-719.

    All information provided is for research purposes only.